Menu
The Goodman Institute Health Blog
  • Home
  • Authors
    • Devon Herrick, Ph.D.
    • John C. Goodman
  • Popular Topics
    • Hits & Misses
    • Artificial Intelligence and Healthcare
    • Doctors & Hospitals
      • COVID-19 and Public Health
    • Policy & Legislation
      • Affordable Care Act
    • Health Economics & Costs
      • Cost of Healthcare
      • Drug Prices & Regulations
      • Health Reform
    • Health Insurance
      • Public Insurance
      • Medicare
    • Telemedicine
      • Medical Tourism
  • Goodman Institute
  • Contact
  • Search
The Goodman Institute Health Blog

Author: Devon Herrick

Leprosy is on the Rise in the United States

Posted on December 28, 2023 by Devon Herrick

Leprosy, also known as Hansen’s disease, is a bacterial infection caused by Mycobacterium leprae and the more recently discovered M. lepromatosis. It is a curable yet neglected tropical disease, entirely treatable with the right care, but nonetheless a disease that still occurs in more than 120 countries.

About 150 cases of leprosy are reported in the US each year. Unique strains of M. leprae have been detected in US patients, though most cases are people who have traveled from countries where leprosy is present or endemic.

+

How Long Do You Want to live… with Alzheimer’s?

Posted on December 27, 2023 by Devon Herrick

Several close family members developed Alzheimer’s or another form of dementia before they died. They all required institutional care. Alzheimer’s is an insidious disease that robs the victims of the person they were. It robs them of the people they loved as they forget the names and faces of family and friends. It robs them of their dignity as they can no longer care for themselves and must be fed, bathed, clothed and toileted like a toddler. It sometimes robs them of their legacy, as their care is so costly they have to bankrupt themselves before qualifying for Medicaid coverage.

+

Counterfeit Weight Loss Drugs Endanger Patients and Profits

Posted on December 26, 2023 by Devon Herrick

Semaglutide is in short supply. That is the generic name for a weight loss drug from the class of glucagon-like peptide 1 (GLP-1) receptor agonists. You may have heard of them under the brand names, Ozempic, Rybelsus, and Wegovy. Injections are taken weekly, and a month’s supply is around $1,400 if paying cash with a GoodRx coupon. Semaglutide is also prescribed for diabetes that does not respond to other treatments. Obese patients can expect to lose anywhere from 15% to 20% of their body weight. That is why it is in high demand and supplies are tight. The drug class is new and it works. Food cravings fall and patients report forgetting to eat. Oprah even admitted taking it.

+

Medical Devices Need Better Quality & Regulatory Compliance

Posted on December 22, 2023 by Devon Herrick

A yearlong investigation into medical device safety risks highlighted numerous medical devices either failed or harmed patients in some way. Most medical devices are not approved as drugs are. Rather, an application is made showing similarity to existing devices. If a device is a novel design a de novo request is made with the FDA. 

+
  • Previous
  • 1
  • …
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • …
  • 219
  • Next

For many years, our health care blog was the only free enterprise health policy blog on the internet. Then, when the NCPA closed its doors, the health blog stopped as well.

During this five-year hiatus no one else has come forward to claim the space. So, my colleagues and I have decided to restart the blog in connection with the Goodman Institute. We invite you and others to use this forum to share your views.

John C. Goodman,

Visit www.goodmaninstitute.org

Subscribe via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 45 other subscribers

Popular Topics

©2026 The Goodman Institute Health Blog | Website by Lexicom